Anti-CD19 [FMC63]

Catalogue Number: AB00613-10.6-ABA

Manufacturer:Vector Laboratories, Inc (ABA)
Type:Recombinant Monoclonal
Alias:B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; Leu12; T-cell surface antigen Leu-12
Shipping Condition:Blue Ice
Unit(s): 200 ug
Host name: Human
Clone: FMC63
Isotype:
Immunogen: Human prolymphocytic leukaemia cell line JVM3.
Application: FACS, FC, IF, IP, IHC, Depl, InVivoA

Additional Text

Gene ID

930

Gene Name

CD19

Uniprot ID

P15391

Purification

Purified

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.

Application Notes

FMC63 was used for four years as a CD19 antibody in various labs prior to its original publication. There, it was reported that the antibody percipitates CD19 and inhibits the binding of other CD19 antibodies to it (Zola et al., 1991; PMID: 1725979). FMC63 was used for IF and FACS of peripheral blood mononuclear cells (PBMC) from patients with multiple myeloma (MM) (Szczepek et al., 1997; PMID: 9057669) and receptor for hyaluronan (HA)-mediated motility (RHAMM) expressing malignant B-lineage cells in myeloma (Crainie et al., 1999; PMID: 10029598). FMC63 was used for IHC and IIP of B cells in lymphocyte-filled villi and IIP of jejunal isolated lymphoid follicle, respectively, in small bowel specimens from human patients (Moghaddami et al., 1998; PMID: 9834269). FNC63 was used to induce B cell depletion in vivo (DiLillo et al., 2011; PMID: 21248259). FMC63 has been incorporated into a CD19 scFv- 41BB- CD3ζ fusion protein-encoding lentiviral vector, which was used in combination with a UCART19 cell therapy to cure high-risk CD19+ infant acute lymphoblastic leukemia (Qasim et al., 2017). This clone did not compete with clone HD37 (available as Ab00214) (Sakemura et al., 2023; PMID: 37879074).

Short Description

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.